ID   K562 NGLY1 KO c20
AC   CVCL_ZL54
SY   NGLY1 KO clone 20; NGLY1c20
DR   ArrayExpress; E-MTAB-7061
DR   PRIDE; PXD010335
DR   Wikidata; Q98126812
RX   PubMed=31659326;
CC   Population: Caucasian.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; 17646; NGLY1.
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 29-06-23; Version: 7
//
RX   PubMed=31659326; DOI=10.1038/s41592-019-0614-5;
RA   Smits A.H., Ziebell F., Joberty G., Zinn N., Mueller W.F.,
RA   Clauder-Munster S., Eberhard D., Falth Savitski M., Grandi P.,
RA   Jakob P., Michon A.-M., Sun H., Tessmer K., Burckstummer T.,
RA   Bantscheff M., Steinmetz L.M., Drewes G., Huber W.;
RT   "Biological plasticity rescues target activity in CRISPR knock outs.";
RL   Nat. Methods 16:1087-1093(2019).
//